Targeted LNP formulation: Antibodies, Aptamers, and Peptides

What is the difference between a targeted LNP and a conventional LNP?
A conventional LNP delivers RNA to the liver by default, driven by apolipoprotein E adsorption onto the particle surface and subsequent recognition by LDL receptors on hepatocytes. A targeted LNP engineers an additional layer of selectivity on top of that baseline, either by attaching a receptor-binding ligand to the particle surface to drive active uptake in a specific cell type, or by modifying lipid composition to shift organ-level biodistribution. The key distinction is that targeted LNPs require explicit validation that the targeting mechanism is functioning in vivo, because adding a ligand does not automatically override the default hepatic tropism.

Why does antibody conjugation sometimes increase liver accumulation instead of reducing it?
Whole antibodies carry an Fc domain that engages Fc-gamma receptors expressed on Kupffer cells and splenic macrophages. This creates a new hepatic clearance route that operates on top of the existing ApoE-LDLR pathway, meaning the total liver signal can be higher for antibody-conjugated LNPs than for untargeted ones, even when the intended target is extrahepatic. Antibody fragments such as F(ab’)2 and Fab remove the Fc domain and avoid this problem, at the cost of added manufacturing complexity.

Can aptamers match antibody targeting performance despite weaker individual binding affinity?
Individual aptamers typically bind their targets with nanomolar to low micromolar affinity, weaker than antibodies for the same receptor. When aptamers are displayed at high density on the LNP surface, however, multiple simultaneous receptor contacts reduce the effective off-rate, improving apparent binding affinity substantially relative to the free aptamer in solution. In some preclinical models, aptamer-conjugated LNPs have achieved targeting efficiency comparable to antibody-conjugated counterparts while producing a cleaner immune profile, though this is context-dependent and cannot be assumed across all targets and formulations.

Why do peptide-targeted LNPs often perform better in vitro than in vivo?
Two mechanisms explain most of the gap. First, in vitro assays are typically run in serum-free or low-serum conditions, so the protein corona does not form and the peptide ligand is fully accessible to the receptor. In vivo, adsorbed plasma proteins can partially occlude the ligand before the particle reaches the target tissue. Second, linear peptides are degraded by circulating proteases with half-lives ranging from minutes to hours, meaning the ligand may no longer be intact by the time the LNP extravasates into the target tissue. Both effects reduce in vivo selectivity relative to what in vitro data predict.

What does the protein corona have to do with ligand selection?
The protein corona is the layer of plasma proteins that adsorbs onto the LNP surface within seconds of intravenous administration. For targeted LNPs, the corona can physically occlude surface-conjugated ligands, reducing their receptor accessibility in vivo. This effect applies to all three ligand classes but is particularly important for antibodies because their large size relative to the PEG layer makes them more susceptible to being buried. Ligand accessibility should be validated under physiological protein concentrations before in vivo targeting claims are made, because serum-free in vitro conditions do not capture this effect.

How do I know which conjugation chemistry to use for my ligand?
The choice depends on the functional groups available on the ligand and on the reactive lipids incorporated into the LNP formulation. Maleimide-thiol chemistry is appropriate for thiol-bearing ligands including reduced antibodies and thiol-modified aptamers, and uses DSPE-PEG-maleimide in the LNP formulation. SPAAC chemistry using DBCO-labeled ligands reacting with azide-LNPs produces a more chemically stable bond and avoids maleimide hydrolysis during dialysis, making it increasingly preferred for antibody and aptamer conjugation. NHS ester chemistry is suitable for amine-bearing ligands including peptides. In all cases, the degree of labeling on the ligand and the molar ratio of reactive lipid in the formulation must be optimized, because both affect conjugation efficiency and particle integrity.

Is any of these three ligand classes clinically validated for LNP targeting?
No. As of early 2026, none of the three ligand classes is clinically validated as an LNP surface targeting approach. Aptamers have clinical precedent as standalone therapeutics, with pegaptanib approved for ocular use and several others reaching early clinical trials, but their use as LNP surface ligands remains preclinical. Antibody-drug conjugates and antibody-nanoparticle systems have been explored in oncology clinical trials with mixed results, but the specific combination of antibody conjugation to ionizable LNPs for RNA delivery has not advanced through late-stage trials. Published clinical outcomes with targeted nanoparticles broadly have been mixed, and the in vivo-to-clinical translation gap should be treated as real and unresolved.

When does surface display density matter more than individual ligand affinity?
Display density becomes the dominant variable when the target cell expresses the receptor at low surface density, because a higher number of ligands per particle increases the probability that at least one productive receptor contact occurs during the brief window of cell-particle proximity. It also matters when the ligand has moderate affinity but fast off-rate, because multivalent display reduces the effective off-rate through avidity. Conversely, when receptor density on the target cell is high and the ligand affinity is already in the picomolar range, adding more ligands per particle produces diminishing returns and may introduce steric problems that reduce rather than improve targeting efficiency.

Why is ligand orientation on the LNP surface important and how does it differ across ligand classes?
A ligand that is attached through its receptor-binding domain rather than away from it cannot engage the receptor productively, even if it is present on the surface. For whole antibodies conjugated through non-site-specific lysine modification, orientation varies across the particle population: some molecules present their Fab arms outward and are functional, others face inward and are not. Aptamers conjugated through a single defined 5′ thiol are uniformly oriented, with the binding domain consistently presented outward. Peptides fall in between, depending on where the conjugation site is placed relative to the binding epitope. Poor orientation effectively reduces functional ligand density below what total conjugation efficiency measurements suggest, which is why orientation control matters independently of how many ligands are attached.

What safety readouts should be included in a preclinical tLNP study?
At minimum: organ-to-body weight ratios for liver and spleen, serum pro-inflammatory cytokines including IL-6 and TNF-alpha, and alanine aminotransferase as a liver injury marker. For antibody-conjugated LNPs, Fc-mediated immune markers deserve particular attention because Fc-FcgR interactions can elevate cytokines independently of the RNA cargo. For programs planning repeat dosing, anti-PEG antibody titers and complement activation markers including C3a and C5a should be added, because accelerated blood clearance on subsequent doses can substantially alter the pharmacokinetic and efficacy profile relative to single-dose data.

How does the cost of aptamer or peptide synthesis compare to antibody production at early development scale?
Antibodies require mammalian cell culture, bioreactor infrastructure, and multi-step purification including protein A affinity chromatography, making them the most expensive option at any scale. Aptamers and peptides are both produced by solid-phase chemical synthesis, which does not require biological systems and scales more predictably. Peptides are the least expensive of the three because their synthesis chemistry is simpler and they do not require the nucleotide phosphoramidite reagents and nuclease-resistance modifications that aptamers typically need. At early development scale where many candidate ligands may need to be screened, the cost difference between peptides or aptamers and antibodies can be substantial enough to influence which ligand class is evaluated first.

At what stage of a program should I commit to a specific ligand class?
Ligand class selection ideally happens before formulation development begins, because the choice determines which reactive lipids go into the LNP, which conjugation chemistry is developed, and which analytical methods need to be built. In practice, many programs start with whole antibodies for proof-of-concept because high-affinity binders are commercially available and the biology can be established quickly, then revisit the ligand class decision when immune profile, manufacturing homogeneity, or repeat-dose pharmacokinetics become priorities. The most expensive scenario is completing formulation and process development for one ligand class and then switching, because conjugation chemistry, purification, and analytical methods may not transfer across classes without significant redevelopment.